Biden Admin Pays Ellume $231M To Build COVID-19 US Test Plant
The government seems to be betting the company’s over-the-counter at-home antigen diagnostic test will be a game changer in stopping the spread of the coronavirus.
You may also be interested in...
The developer of the at-home over-the-counter antigen test — the first of its kind to get an emergency use authorization from the FDA – received more than $200m from the government to manufacture in the US. So what’s next for Ellume? In this Medtech Insight case study Q&A, the Australian company’s CEO, Sean Parson, explains.
After the US government invested almost half a billion dollars to ensure Cue Health could scale up production, the FDA announced the self-administered test will now be available over the counter.
Ellume Health’s COVID-19 Home Test isn’t just a relatively fast, accurate and easy-to-administer antigen diagnostic, but it’s also available over-the-counter, which greatly expands public access to such tests.